Product Description
Mechanisms of Action: CDK1 Inhibitor,CDK2 Inhibitor,CDK3 Inhibitor,CDK4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02656849 | P2 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2019-10-01 |
|
| JapicCTI-142520 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-02-28 |
|
| JapicCTI-152872 | P2 |
Terminated |
Small Cell Lung Cancer |
2016-10-30 |
|
| NCT02522910 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2016-08-01 |